Scholarlink

Purpose <p>Tubularized bladder mucosa technique was introduced for managing recurrent vesicoureteral reflux after failed reimplantation. Its application in cases of primary vesicoureteral reflux has not previously been reported. This prospective cohort study compares the tubularized bladder mucosa technique with the established Politano-Leadbetter procedure for the treatment of primary vesicoureteral reflux.</p> Methods <p>Patients with a confirmed diagnosis of primary vesicoureteral reflux who met the inclusion criteria were enrolled. They were prospectively assigned to either the tubularized bladder mucosa group or the Politano-Leadbetter group. The outcomes included vesicoureteral reflux recurrence rates at 3 months, febrile urinary tract infection incidence and postoperative development of ureterovesical junction stenosis.</p> Results <p>Between January 2024 and January 2025, 56 children (84 ureters) with median age 38.07 months were were enrolled and assigned to either tubularized bladder mucosa (27 patients/40 ureters) or Politano-Leadbetter group (29 patients/44 ureters). The tubularized bladder mucosa group demonstrated significantly shorter operative times (108.15 ± 16.25 vs. 123.79 ± 25.67&#xa0;min, <i>p</i> = 0.018). During the 3-month follow-up, no significant differences were observed between the two groups in terms of vesicoureteral reflux recurrence rate (<i>p</i> = 0.43) or febrile urinary tract infection rate (<i>p</i> = 0.97). No cases of ureterovesical junction stenosis occurred in either group.</p> Conclusions <p>This study demonstrates that the tubularized bladder mucosa technique is a safe and effective treatment treatment for primary vesicoureteral reflux, with excellent short-term outcomes comparable to those of conventional procedures. Its distinct advantages - including procedural simplicity, minimal tissue dissection, and shorter operative duration - position it as an ideal candidate for pneumovesicoscopic adaptation.</p> Trial registration number <p>ChiCTR2400081850; Date: March 15th, 2024.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tubularized bladder mucosa technique compared with Politano-Leadbetter procedures for treating primary vesicoureteral reflux in the pediatric population: a prospective cohort study

  • 期刊论文

  • 发表日期：

    2025年11月10日

查看全文
  • Chuan Wang,
  • Li Zeng,
  • Xiaojie Tang,
  • Lugang Huang

摘要

Purpose

Tubularized bladder mucosa technique was introduced for managing recurrent vesicoureteral reflux after failed reimplantation. Its application in cases of primary vesicoureteral reflux has not previously been reported. This prospective cohort study compares the tubularized bladder mucosa technique with the established Politano-Leadbetter procedure for the treatment of primary vesicoureteral reflux.

Methods

Patients with a confirmed diagnosis of primary vesicoureteral reflux who met the inclusion criteria were enrolled. They were prospectively assigned to either the tubularized bladder mucosa group or the Politano-Leadbetter group. The outcomes included vesicoureteral reflux recurrence rates at 3 months, febrile urinary tract infection incidence and postoperative development of ureterovesical junction stenosis.

Results

Between January 2024 and January 2025, 56 children (84 ureters) with median age 38.07 months were were enrolled and assigned to either tubularized bladder mucosa (27 patients/40 ureters) or Politano-Leadbetter group (29 patients/44 ureters). The tubularized bladder mucosa group demonstrated significantly shorter operative times (108.15 ± 16.25 vs. 123.79 ± 25.67 min, p = 0.018). During the 3-month follow-up, no significant differences were observed between the two groups in terms of vesicoureteral reflux recurrence rate (p = 0.43) or febrile urinary tract infection rate (p = 0.97). No cases of ureterovesical junction stenosis occurred in either group.

Conclusions

This study demonstrates that the tubularized bladder mucosa technique is a safe and effective treatment treatment for primary vesicoureteral reflux, with excellent short-term outcomes comparable to those of conventional procedures. Its distinct advantages - including procedural simplicity, minimal tissue dissection, and shorter operative duration - position it as an ideal candidate for pneumovesicoscopic adaptation.

Trial registration number

ChiCTR2400081850; Date: March 15th, 2024.